Home » Stocks » EKSO

Ekso Bionics Holdings, Inc. (EKSO)

Stock Price: $4.07 USD -0.11 (-2.63%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $4.26 +0.19 (4.67%) Oct 30, 5:51 PM

Stock Price Chart

Key Info

Market Cap 33.85M
Revenue (ttm) 10.77M
Net Income (ttm) -16.82M
Shares Out 8.32M
EPS (ttm) -3.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $4.07
Previous Close $4.18
Change ($) -0.11
Change (%) -2.63%
Day's Open 4.20
Day's Range 3.96 - 4.31
Day's Volume 113,023
52-Week Range 2.25 - 11.40

More Stats

Market Cap 33.85M
Enterprise Value 24.44M
Earnings Date (est) Mar 16, 2021
Ex-Dividend Date n/a
Shares Outstanding 8.32M
Float 7.42M
EPS (basic) -2.92
EPS (diluted) -3.05
FCF / Share -1.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 195,662
Short Ratio 1.83
Short % of Float 2.64%
Beta 2.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.14
PB Ratio 11.00
Revenue 10.77M
Operating Income -14.50M
Net Income -16.82M
Free Cash Flow -11.81M
Net Cash 9.41M
Net Cash / Share 1.13
Gross Margin 62.80%
Operating Margin -134.65%
Profit Margin -156.10%
FCF Margin -109.64%
ROA -37.18%
ROE -625.59%
ROIC -266.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.50*
(157.99% upside)
Low
9.00
Current: $4.07
High
12.00
Target: 10.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue13.9211.337.3514.228.665.333.302.71
Revenue Growth22.81%54.11%-48.29%64.2%62.59%61.33%22.03%-
Gross Profit6.764.312.072.951.181.560.590.37
Operating Income-16.64-27.03-31.94-27.78-21.56-16.79-10.29-14.24
Net Income-12.13-26.99-29.12-23.47-19.59-33.77-11.89-15.04
Shares Outstanding4.794.082.371.210.970.750.200.19
Earnings Per Share-2.55-6.60-12.30-30.75-27.45-45.30-59.85-78.74
Operating Cash Flow-15.77-22.17-31.23-25.00-18.27-15.01-9.06-12.66
Capital Expenditures-0.06-0.13-0.46-1.10-1.49-1.49-0.38-0.83
Free Cash Flow-15.83-22.30-31.68-26.09-19.76-16.49-9.44-13.49
Cash & Equivalents10.877.6627.8116.8519.5525.190.811.74
Total Debt3.874.986.976.790.080.047.577.69
Net Cash / Debt7.002.6720.8410.0619.4725.15-6.76-5.96
Assets21.9217.6637.9924.4332.2033.476.586.21
Liabilities15.1214.9316.6017.8923.3910.6715.6314.62
Book Value6.802.7321.396.538.8122.80-36.37-25.09
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ekso Bionics Holdings, Inc.
Country United States
Employees 67
CEO Jack Peurach

Stock Information

Ticker Symbol EKSO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: EKSO

Description

Ekso Bionics Holdings designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, Africa, and internationally. The company operates through EksoHealth and EksoWorks segments. It primarily offers EksoNR, a bionic suit that provides the ability to stand and walk over ground with a full weight-bearing, reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke; and EksoUE, a wearable assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms, as well as reduce fatigue while rehabilitation sessions to achieve a larger active range of motion. The company's Ekso devices are primarily used in a hospital and rehabilitation setting. It has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.